Actively Recruiting
Evaluating Gemcitabine with Ivonescimab for Advanced NSCLC After Chemoimmunotherapy Progression A Multicenter Single-Arm Phase II Trial
Led by Swiss Cancer Institute · Updated on 2026-10-28
47
Participants Needed
8
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment approach for patients with advanced non-small cell lung cancer NSCLC who have experienced disease progression after chemoimmunotherapy. This Phase II trial studies the combination of gemcitabine, a chemotherapy drug known for its immunostimulatory effects, with ivonescimab, a bispecific antibody targeting PD-1 and VEGF pathways. The study aims to assess if this combination can improve tumor response using RECIST v1.1 criteria, addressing the limited options available after standard treatments fail. Participants will receive gemcitabine according to standard protocols, combined with ivonescimab administered at 20 mgkg every three weeks. Ivonescimab works by targeting immune checkpoints and tumor blood vessel growth, potentially enhancing the immune systems attack on cancer. The trial is single-arm and open-label, meaning all participants receive the combination treatment, and the research team monitors responses over time. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests to monitor blood counts and organ function, and evaluations of side effects. The main outcome is the objective response rate at the end of treatment, with follow-up measuring duration of response and progression-free survival for up to two years. The study ensures diverse participant inclusion and tracks safety throughout the treatment and observation periods.
CONDITIONS
Brief Title
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
Research Team
J
Jana Musilova, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here